Description: GRAIL, LLC, a biotechnology company, focuses on developing technologies for early cancer detection. The company develops Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. It is also developing minimal residual disease and other post-diagnostic tests. GRAIL, LLC was formerly known as PSC15, Inc. and changed its name to GRAIL, LLC in January 2016. The company was incorporated in 2015 and is based in Menlo Park, California. GRAIL, LLC operates as a subsidiary of Illumina, Inc.
Home Page: grail.com
1525 O’Brien Drive
Menlo Park,
CA
94025
United States
Phone:
833-694-2553
Officers
| Name | Title |
|---|---|
| Mr. Robert P. Ragusa | Chief Executive Officer |
| Dr. Joshua J. Ofman M.D., M.S.H.S | President |
| Mr. Aaron Freidin | Chief Financial Officer |
| Mr. Paul Ciccolella | Senior VP of Global Development & Operations |
| Ms. Amoolya Singh Ph.D. | Senior VP of Research & Chief Scientific Officer |
| Mr. Abram Barth J.D., M.P.H. | General Counsel |
| Ms. Julie Currie | Chief People Officer |
| Mr. Rodger Currie | VP and Head of Government Affairs & Alliance Development |
| Mr. Gautam K. Kollu | Chief Commercial Officer |
| Sir Harpal S. Kumar M.A., M.B.A., MA, MBA, MEng | President Biopharma Business & Europe |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2024-06-12 |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |